Systemically administered STO-609 decreases tumour growth, both as a single agent and additively in combination with AR inhibition, in a C4-2B prostate cancer xenograft model [91], and in the DEN-induced hepatocellular carcinoma mouse model [86], demonstrating that CaMKK inhibition is a valid strategy for the treatment of prostate and hepatic cancer, and based on the in vitro studies, may potentially be suitable for other cancer types, including AML, gastric and ovarian cancers. Here, CAMKK2 is linked to neoplasm.